VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Asia 2022 | The EXTREME regimen for head and neck cancer

Avinash Khadela • 29 Nov 2022
ESMO Asia 2022
Head and Neck Cancer
Immuno-Oncology

Avinash Khadela, PhD, L.M. College Of Pharmacy, Ahmedabad, India, explains the EXTREME regimen of cetuximab, cisplatin, and 5-fluorouracil and its role in the treatment of head and neck cancer. This interview took place at the European Society for Medical Oncology (ESMO) Asia congress 2022 in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Avinash Khadela

2:54
EXTREME regimen vs. cetuximab + cisplatin + paclitaxel for recurrent/metastatic head and neck cancer
Avinash Khadela • 29 Nov 2022
2:47
Improving outcomes for patients with head and neck cancer
Avinash Khadela • 29 Nov 2022

Related Videos

3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
2:00
Durvalumab plus danvatirsen for R/M HNSCC: exciting SCORES data
Ezra Cohen
3:10
The risks of radioactive iodine treatment in thyroid cancer
Remco Molenaar
0:58
Checkpoint inhibitors for head and neck cancer in the definitive setting?
Barbara Burtness
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals